Compare USAS & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USAS | ATAI |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | Canada | Netherlands |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.4B |
| IPO Year | N/A | 2021 |
| Metric | USAS | ATAI |
|---|---|---|
| Price | $5.34 | $3.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $4.08 | ★ $14.33 |
| AVG Volume (30 Days) | ★ 5.3M | 3.4M |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $104,867,000.00 | $3,018,000.00 |
| Revenue This Year | $20.47 | $943.18 |
| Revenue Next Year | $91.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 811.78 |
| 52 Week Low | $0.95 | $1.15 |
| 52 Week High | $6.24 | $6.75 |
| Indicator | USAS | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 53.50 | 45.58 |
| Support Level | $4.85 | $3.64 |
| Resistance Level | $5.70 | $4.14 |
| Average True Range (ATR) | 0.35 | 0.24 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 38.13 | 33.33 |
Americas Gold And Silver Corp is a mining company engaged in the acquisition, exploration, development, and production of precious metals mineral properties in Mexico and the United States. The company's primary operating assets, which are also its reporting segments, are the Cosala operations, the Galena Complex, and Relief Canyon. It also holds interests in the San Felipe Development Project located in Sonora, Mexico. The Cosala operations segment, which derives maximum revenue, operates in Mexico, while the Galena Complex and Relief Canyon segments operate in the United States.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.